PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
43.33%
Some net income increase while AXSM is negative at -43.70%. John Neff would see a short-term edge over the struggling competitor.
-26.41%
Negative yoy D&A while AXSM is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-627.56%
Negative yoy deferred tax while AXSM stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
174.63%
SBC growth while AXSM is negative at -31.54%. John Neff would see competitor possibly controlling share issuance more tightly.
-214.26%
Negative yoy working capital usage while AXSM is 748.90%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-295.13%
Negative yoy AP while AXSM is 655.58%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-30.84%
Negative yoy usage while AXSM is 225.43%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
848.72%
Well above AXSM's 128.07%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-15.17%
Negative yoy CFO while AXSM is 40.48%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
100.00%
CapEx growth of 100.00% while AXSM is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth of 100.00% while AXSM is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
100.00%
We expand invests by 100.00% while AXSM is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
-2235.51%
Both yoy lines negative, with AXSM at -1114.29%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
219.76%
Issuance growth of 219.76% while AXSM is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.